NUV-1511 Phase 1/2 Trial Begins with First Patient Dosing for Advanced Tumor Treatment

Nuvation Bio, a biopharmaceutical firm focused on addressing critical needs in cancer treatment, has initiated clinical trials for its first drug-drug conjugate (DDC), NUV-1511. The Phase 1/2 study marks a pivotal moment for the company's innovative platform, which aims to develop potent cancer-fighting drugs that target cancer cells while sparing healthy tissues. David Hung, the company's CEO, emphasized the significance of this achievement for Nuvation Bio's DDC technology, which is central to the company's founding principles.
The clinical trial is designed with flexibility to explore two dosing schedules for NUV-1511, with the primary objectives of determining the optimal Phase 2 dosage and evaluating the drug's safety, pharmacokinetics, and potential clinical benefits. The study will involve patients with various types of advanced solid tumors, including those who have not responded to treatments such as Enhertu® and Trodelvy®, as well as those with specific types of breast, prostate, pancreatic, and ovarian cancers.
Nuvation Bio, established in 2018 by David Hung, is dedicated to creating novel therapeutics for challenging cancers. The company's portfolio comprises a range of oncology therapeutics, each targeting different forms of cancer. Hung, who also founded Medivation, Inc., which developed a leading prostate cancer treatment, has brought his expertise to Nuvation Bio, which maintains a presence in both New York and San Francisco.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!